"The gaps to fill are significant when you think about replacing drugs that achieve peak sales north of $20 billion or $30 billion drug before patent exclusivity expires," Roop told Business Insider in a recent interview.
"Large, successful pharmaceutical companies can become victims of their own successes when patents run out on blockbuster treatments," he added.
"Developing brand new drugs is a long, expensive, and risky process, so acquisitions of other companies with new medications in their pipelines offer a potentially faster way to generate new revenue."
"As industry giants face patent expiration for some of their best-selling drugs, pharma companies look at areas such as obesity to supplement growth," Jefferies' Chris Roop said.
Collection
[
|
...
]